Rezolute, Inc.
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Transaction led by Frazier Life Sciences with participation from new and existing funds
Company newsroom
NASDAQ:RZLT
2 releases
Transaction led by Frazier Life Sciences with participation from new and existing funds
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation